Hypopituitarism Market on Track for Major Expansion by 2032, According to DelveInsight
The Key Hypopituitarism Companies in the market include - Ascendis Pharma, Lumos Pharma, Novartis, Pfizer, Eli Lilly and Company, Merck & Co., AbbVie, Novo Nordisk, Sanofi, AstraZeneca, Teva Pharmaceutical Industries, Ferring Pharmaceuticals, and others.
DelveInsight's 'Hypopituitarism Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hypopituitarism, historical and forecasted epidemiology as well as the Hypopituitarism market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Hypopituitarism Market Report:
The Hypopituitarism market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
In December 2024, OPDIVO QVANTIG may lead to primary or secondary adrenal insufficiency, immune-related hypophysitis, immune-mediated thyroid conditions, and Type 1 diabetes mellitus, which can present with diabetic ketoacidosis. Depending on the severity, OPDIVO QVANTIG should be withheld [refer to section 2 Dosage and Administration in the Full Prescribing Information]. For Grade 2 or higher adrenal insufficiency, initiate appropriate symptomatic management, including hormone replacement therapy if needed. Hypophysitis may manifest with acute symptoms like headaches, sensitivity to light, or vision disturbances due to mass effect. It may also result in hypopituitarism, requiring hormone replacement as clinically appropriate.
Hypopituitarism is anticipated to have a global incidence rate of 4.2 cases per 100,000 people annually, with a prevalence of 45.5 cases per 100,000, showing no distinction between genders.
The FDA granted approval for the use of Skytrofa (lonapegsomatropin) in September 2021 for the treatment of pediatric patients aged one year and older who weigh at least 11.5 kg and have growth failure as a result of insufficient endogenous growth hormone secretion
The study by Rogol stated that GHD in children is a relatively rare condition. In the United States, it was estimated to occur in approximately 1 in 3500 to 4000 children
As per National Institute for Health and Clinical Excellence (NICE), the prevalence of growth hormone deficiency was estimated to be between 1 in 3500 and 1 in 4000 children
In about half of the children with growth hormone deficiency (50%), the cause is unknown (idiopathic growth hormone deficiency)
Key Hypopituitarism Companies: Ascendis Pharma, Lumos Pharma, Novartis, Pfizer, Eli Lilly and Company, Merck & Co., AbbVie, Novo Nordisk, Sanofi, AstraZeneca, Teva Pharmaceutical Industries, Ferring Pharmaceuticals, and others
Key Hypopituitarism Therapies: Lonapegsomatropin, LUM-201, somapacita, and others
The Hypopituitarism market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hypopituitarism pipeline products will significantly revolutionize the Hypopituitarism market dynamics.
Hypopituitarism Overview:
Hypopituitarism is a rare disorder in which the pituitary gland, located at the base of the brain, fails to produce one or more of its hormones or produces them in insufficient amounts. These hormones regulate essential functions such as growth, reproduction, and metabolism. Causes of hypopituitarism can include tumors, head injuries, infections, or autoimmune conditions. Symptoms vary depending on which hormones are deficient and may include fatigue, weakness, weight loss, infertility, and growth problems. Treatment usually involves hormone replacement therapy to restore normal body functions.
Hypopituitarism Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Hypopituitarism Epidemiology Segmentation:
The Hypopituitarism market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Download the report to understand which factors are driving Hypopituitarism epidemiology trends @ Hypopituitarism Epidemiology Forecast
Hypopituitarism Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hypopituitarism market or expected to get launched during the study period. The analysis covers Hypopituitarism market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Hypopituitarism Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Hypopituitarism Therapies and Key Companies
Scope of the Hypopituitarism Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Hypopituitarism Companies: Ascendis Pharma, Lumos Pharma, Novartis, Pfizer, Eli Lilly and Company, Merck & Co., AbbVie, Novo Nordisk, Sanofi, AstraZeneca, Teva Pharmaceutical Industries, Ferring Pharmaceuticals, and others
Key Hypopituitarism Therapies: Lonapegsomatropin, LUM-201, somapacitan, and others
Hypopituitarism Therapeutic Assessment: Hypopituitarism current marketed and Hypopituitarism emerging therapies
Hypopituitarism Market Dynamics: Hypopituitarism market drivers and Hypopituitarism market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Hypopituitarism Unmet Needs, KOL's views, Analyst's views, Hypopituitarism Market Access and Reimbursement
To know more about Hypopituitarism companies working in the treatment market, visit @ Hypopituitarism Clinical Trials and Therapeutic Assessment
Table of Contents
1. Hypopituitarism Market Report Introduction
2. Executive Summary
3. SWOT analysis
4. Hypopituitarism Patient Share (%) Overview at a Glance
5. Hypopituitarism Market Overview at a Glance
6. Hypopituitarism Disease Background and Overview
7. Hypopituitarism Epidemiology and Patient Population
8. Country-Specific Patient Population of Hypopituitarism
9. Hypopituitarism Current Treatment and Medical Practices
10. Hypopituitarism Unmet Needs
11. Hypopituitarism Emerging Therapies
12. Hypopituitarism Market Outlook
13. Country-Wise Hypopituitarism Market Analysis (2018–2030)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Hypopituitarism Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
4 days ago
- Globe and Mail
Multiple Sclerosis Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, 'Multiple sclerosis Pipeline Insight 2025' report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Multiple sclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Multiple Sclerosis Treatment Landscape. Click here to read more @ Multiple Sclerosis Pipeline Outlook Key Takeaways from the Multiple Sclerosis Pipeline Report In May 2025, Novartis Pharmaceuticals announced a Phase IV study in which breastfeeding mothers treated with ofatumumab and their babies are taking part for up to 1 year. The study consists of a Core Part and a Safety Follow-up Part. The Core Part includes a Screening period and a Sampling period. During the Screening period (up to 4 weeks), the study doctor will assess if mothers can join the study. The Sampling period, during which milk samples and a blood sample will be collected, will last for up to 12 weeks. The Safety Follow-up Part will last for about 9 months, to follow up on health and safety of mothers and their babies. In May 2025, Hoffmann-La Roche announced a study will evaluate the physical impact of MS from participant's perspective, provide continued access to ocrelizumab and assess the safety and tolerability of ocrelizumab. In May 2025, Eli Lilly and Company conducted a study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better. The study will last about 9 months with additional 6 months follow-up. In May 2025, Biocad announced a clinical study is to assess the long-term efficacy and safety of BCD-132 (divozilimab) in patients with multiple sclerosis who previously participaded in BCD-132-2 and BCD-132-4/MIRANTIBUS studies. In May 2025, Sanofi conducted a study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to 36 months double-blind administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. In May 2025, Biogen organized a study is to assess the efficacy of DMF in Chinese participants with RMS at Week 48. The secondary objectives of the study are to assess the efficacy and safety of DMF in Chinese participants with RMS. DelveInsight's Multiple Sclerosis pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Multiple Sclerosis treatment. The leading Multiple Sclerosis Companies such as Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., and ImCyse and others. Promising Multiple Sclerosis Therapies such as 11C-BMS-986196, ofatumumab, Fingolimod, Siponimod, elezanumab, Alemtuzumab, Tecfidera, and others. Stay informed about the cutting-edge advancements in Multiple Sclerosis treatments. Download for updates and be a part of the revolution in cancer care @ Multiple Sclerosis Clinical Trials Assessment Multiple sclerosis Emerging Drugs Profile IMU-838: Immunic Therapeutics Vidofludimus calcium (IMU-838) is a small molecule investigational drug under development as an oral tablet formulation for the treatment of relapsing-remitting multiple sclerosis, or RRMS, inflammatory bowel disease, or IBD, and other chronic inflammatory and autoimmune diseases. Bolstered by excellent clinical data from the phase II EMPhASIS trial, Immunic believed that vidofludimus calcium has the potential to demonstrate medically important advantages compared with other treatments, particularly for the early treatment of RMS patients, due to its placebo like safety profile and its robust anti-inflammatory and neuroprotective properties. BIIB091: Biogen BIIB091 selectively inhibits Burton's tyrosine kinase (BTK), a non-receptor tyrosine kinase that regulates the development and signaling of B cells and myeloid cells hypothesized to contribute to MS pathogenesis. In addition, BTK has been demonstrated to play a key role in the activation of another cell of the immune system, the myeloid cells via another receptor of this cell (Fcγ receptor signaling (FcγRs)). Preclinical studies demonstrated BIB091 to be a high potency molecule with good drug-like properties and a safety/tolerability profile suitable for clinical development as a highly selective, reversible BTKi for treating autoimmune diseases such as MS. Currently, the drug is in the Phase II stage of its development for the treatment of Multiple sclerosis. IMCY-0141: ImCyse IMCY-0141 is the Company's second clinical-stage compound. This Imotope is designed based on MOG (Myelin Oligodendrocyte Glycoprotein) with the aim to halt the progression of multiple sclerosis (MS) by stopping the body's immune system from attacking the central nervous system and disrupting undesirable autoimmune responses that drive the destruction of the myelin sheath protecting the nerves. IMCY-0141 has shown promising results in several MS preclinical models, demonstrating an immune response that supports the proposed mode of action and inducing a memory response so that the treatment effect is long-lasting and requires less frequent dosing regimens. Also, if treatment is begun early enough, it has the potential to allow patients to live with minimal impact from the disease. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of multiple sclerosis. NeuroVax: Immune Response BioPharma NeuroVax contains a combination of three protein fragments (peptides) which appear on the surface of T-cells involved in the immune response in MS. Studies suggested that treatment with NeuroVax stimulates production of certain regulatory T-cells, which in turn decrease the levels of other T-cells which attack myelin. NeuroVax is a Once a Month Dosing injection, safe, tolerable, enhances FOXP3+ Tregs & Regulates Pathogenic T Cells in MS Patients, a first in class disease modifying Multiple Sclerosis Vaccine. NeuroVax IR has been shown to stimulate strong, disease-specific cell-mediated immunity in nearly all treated patients. NeuroVax appears to work in part by enhancing levels of Foxp3+ Tregs, which may help regulate expression of pathogenic T cells in MS patients. The three TCR peptides combined in it correspond to one or more TCR gene families which are over expressed in 90% of MS patients. The Multiple Sclerosis Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Multiple Sclerosis with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple Sclerosis Treatment. Multiple Sclerosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Multiple Sclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different Multiple Sclerosis mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple Sclerosis market Learn more about Multiple Sclerosis Drugs opportunities in our groundbreaking Multiple Sclerosis research and development projects @ Multiple Sclerosis Unmet Needs Multiple Sclerosis Companies Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., and ImCyse and others. Multiple sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Multiple Sclerosis Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Discover the latest advancements in Multiple Sclerosis treatment by visiting our website. Stay informed about how we're transforming the future of neurology @ Multiple Sclerosis Market Drivers and Barriers, and Future Perspectives Scope of the Multiple Sclerosis Pipeline Report Coverage- Global Multiple Sclerosis Companies- Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., and ImCyse and others. Multiple Sclerosis Therapies- 11C-BMS-986196, ofatumumab, Fingolimod, Siponimod, elezanumab, Alemtuzumab, Tecfidera, and others. Multiple Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Multiple Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of Multiple Sclerosis Pipeline on our website @ Multiple Sclerosis Emerging Drugs and Companies Table of Content Introduction Executive Summary Multiple sclerosis: Overview Pipeline Therapeutics Therapeutic Assessment Multiple sclerosis – DelveInsight's Analytical Perspective Late Stage Products (Phase III) IMU-838: Immunic Therapeutics Drug profiles in the detailed report….. Mid Stage Products (Phase II) BIIB091: Biogen Drug profiles in the detailed report….. Early Stage Products (Phase I) NeuroVax: Immune Response BioPharma Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Multiple sclerosis Key Companies Multiple sclerosis Key Products Multiple sclerosis- Unmet Needs Multiple sclerosis- Market Drivers and Barriers Multiple sclerosis- Future Perspectives and Conclusion Multiple sclerosis Analyst Views Multiple sclerosis Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
16-05-2025
- Globe and Mail
Aplastic Anemia Market to Witness Significant Growth by 2034, Fueled by Rising Prevalence and a Strong Pipeline
The aplastic anemia treatment market is poised for significant growth, with key pharmaceutical companies including Novartis, Pfizer, Teva Pharmaceuticals, Kyowa Kirin, Regeneron Pharmaceuticals, Gamida Cell, and others leading therapeutic innovation in this rare hematologic disorder. DelveInsight's " Aplastic Anemia Market Insight, Epidemiology And Market Forecast - 2034" report provides an in-depth understanding of aplastic anemia, including historical and forecasted epidemiology as well as market trends across the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. According to the comprehensive analysis, the aplastic anemia market, valued at approximately USD 270 million in 2023 across the 7MM, is projected to expand substantially through 2034, fueled by increasing disease incidence, growing uptake of existing therapies, and the anticipated launch of promising pipeline candidates. Furthermore, the US currently dominates the aplastic anemia treatment landscape, accounting for approximately 70% of the market share in the 7MM, followed by Japan with the second-highest market value at approximately USD 35 million in 2023. Among European nations, Germany leads the market, with additional growth anticipated across all regions during the forecast period. Download the Aplastic Anemia Market Forecast Report to understand which factors are driving the Aplastic Anemia market @ Aplastic Anemia Market Trends. DelveInsight's aplastic anemia epidemiological analysis reveals that Japan reported the highest aplastic anemia incident cases, contributing approximately 30% of cases across the 7MM in 2023. Notably, 56% of aplastic anemia cases were reported in individuals aged 60 and above, while 43% were below the age of 60. Discover evolving trends in the Aplastic Anemia patient pool forecasts @ Aplastic Anemia Epidemiological Analysis. The current aplastic anemia treatment varies based on patient age and disease severity. Hematopoietic stem cell transplantation (HSCT) remains the standard of care for patients under 40 years, while immunosuppressive therapy (IST) is preferred for those above 40 years. Novartis' PROMACTA / REVOLADE (eltrombopag) currently leads market revenue, followed by various immunosuppressive therapies. However, younger patients experience significantly better long-term survival compared to those aged 60 and above, highlighting a critical unmet need for improved management strategies in older populations. The aplastic anemia therapeutic landscape is evolving with several marketed and emerging options. ALVAIZ (eltrombopag choline) from Teva Pharmaceuticals (NYSE: TEVA), an oral thrombopoietin receptor agonist that stimulates platelet production, approved in November 2023, represents an important treatment advancement. In Japan, Kyowa Kirin's ROMIPLATE has gained approval for patients showing inadequate response to conventional therapy. The patent for PROMACTA (eltrombopag), a key treatment for aplastic anemia, is set to expire on July 13, 2025. This expiry will likely lead to the introduction of generic versions, which can reduce treatment costs and increase patient access. As Promacta is currently a leading therapy in the aplastic anemia market, the availability of generics is expected to intensify competition, lower prices, and potentially shift prescribing patterns. Looking toward future market growth, promising pipeline candidates include REGN7257 from Regeneron Pharmaceuticals (NASDAQ: REGN), a gamma chain cytokine receptor antibody targeting the common gamma chain found in various interleukin receptors. Currently in Phase I/II clinical trials, this therapy aims to address T-cell-mediated pathogenesis in severe aplastic anemia patients who have relapsed after immunosuppressive therapy. Another noteworthy emerging therapy is OMISIRGE (omidubicel) by Gamida Cell (NASDAQ: GMDA), a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy derived from cord blood. In April 2025, CK0801, an allogeneic T regulatory (Treg) cell therapy manufactured by Cellenkos, received FDA Orphan Drug Designation for aplastic anemia, supporting its development as a novel treatment for this rare condition. A Phase III registration trial is planned for the second half of 2025, positioning CK0801 as a promising non-immunosuppressive option for aplastic anemia patients unresponsive to standard therapies. Discover evolving trends in the Aplastic Anemia treatment landscape @ Aplastic Anemia Recent Developments. Despite therapeutic advances, significant challenges remain in the aplastic anemia treatment landscape. Finding effective and well-tolerated treatments for patients who do not respond to standard therapies or who are unsuitable candidates for aggressive interventions continues to be problematic. Additionally, poor survival rates among older patients represent a substantial unmet medical need requiring innovative approaches. Table of Contents 1. Key Insights 2. Executive Summary of Aplastic Anemia 3. Aplastic Anemia Competitive Intelligence 4. Aplastic Anemia: Market Overview at a Glance 5. Aplastic Anemia: Disease Background and Overview 6. Patient Journey 7. Aplastic Anemia Epidemiology and Patient Population 8. Treatment Algorithm, Current Treatment, and Medical Practices 9. Aplastic Anemia Unmet Needs 10. Key Endpoints of Aplastic Anemia Treatment 11. Aplastic Anemia Marketed Products 12. Aplastic Anemia Emerging Therapies 13. Aplastic Anemia: Seven Major Market Analysis 14. Attribute analysis 15. 7MM: Market Outlook 16. Access and Reimbursement Overview of Aplastic Anemia 17. KOL Views 18. Aplastic Anemia Market Drivers 19. Aplastic Anemia Market Barriers 20. Appendix 21. DelveInsight Capabilities 22. Disclaimer 23. About DelveInsight Related Reports Aplastic Anemia Pipeline Insight Aplastic Anemia Pipeline Insight provides comprehensive insights about the Aplastic Anemia pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Aplastic Anemia companies, including Gamida-Cell, Regeneron Pharmaceuticals, and BioLineRx, among others. About DelveInsight DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Arpit Anand Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
Cision Canada
14-05-2025
- Cision Canada
Novartis Canada extends Health Equity Initiative effort, fueling innovation and impact for second year Français
MONTREAL, May 14, 2025 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is pleased to announce the launch of the second edition Health Equity Initiative. Aimed at promoting equitable healthcare for Canadians by addressing health disparities, Novartis Canada will award $500,000 to non-profit projects focused on improving health equity and addressing the unique healthcare challenges faced by underserved and marginalized populations. According to the World Health Organization, health equity is achieved when everyone can attain their full potential for health and well-being. i However, despite having a universal healthcare system, Canada ranks third to last with respect to equity in healthcare access and experience among nine peer countries, highlighting persistent challenges faced by underserved communities. ii The 2025 Health Equity Initiative aims to address Canada's existing healthcare access inequity by supporting individuals and organizations that are fully immersed in their communities, understand their unique needs, and are dedicated to advancing fair access to healthcare. By empowering these agents of change, Novartis seeks to inspire broader community engagement and action to improve healthcare outcomes. Sustaining the momentum from the inaugural Health Equity Initiative in 2024, Novartis will be awarding additional grants to support Canadian non-profit and/or charitable organizations that are pioneering innovative solutions towards equitable healthcare. "We are incredibly proud to continue our commitment to supporting health equity in Canada by launching the second year of this Initiative," said Mark Vineis, Country President, Novartis Canada. "All Canadians deserve equitable access to healthcare and Novartis believes in the power of supporting sustainable, grassroots projects that help advance health equity for underserved communities." In total, more than 130 applications for funding were received in the Initiative's first year. The 2024 winners were selected through a thorough evaluation process designed in collaboration with Equity Mobilizing Partnerships in Community (EMPaCT), each exemplifying the spirit and impact of the Initiative through their innovative approaches to addressing and improving health equity: Black Physicians of Canada: By creating a national database of Black physicians across Canada, this project is to tackling health disparities and improving access to culturally sensitive care, ensuring that Black patients receive health services that acknowledge and respect their unique needs. The development of a Black health digital hub further enhances connectivity and resource sharing among healthcare providers and patients. Foundations for Social Change: This project addresses the health equity challenges faced by those transitioning out of homelessness and extreme poverty in Vancouver by implementing a comprehensive support system – including mental health services, healthcare navigation support and direct cash transfers – to empower individuals with the tools and resources needed to improve health outcomes. Fort Severn First Nation: The northernmost community in Ontario, this project focuses on bridging the healthcare access gap for First Nations communities. By establishing a team of community health coordinators known as Payukotayno Meno ya win, the initiative ensures timely diagnosis and treatment, as well as access to preventative care. These efforts promote greater engagement between families and the healthcare system, fostering trust and improving overall health outcomes within the community. "The Health Equity Initiative's 2024 winners have set a powerful precedent, showcasing the impact of a community-based focus on innovation and collaboration," says Vineis. "Novartis Canada recognizes the importance of supporting community organizations and is committed to supporting all future winners in their missions to drive meaningful action." How to apply for funding Canadian non-profit and/charitable organizations that are passionate about advancing health equity and committed to creating a more inclusive healthcare system are encouraged to learn more and apply for funding by visiting The deadline for applications is 11:59 p.m. PT on June 16, 2025 About Novartis Novartis is a focused innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. In Canada, Novartis Pharmaceuticals Canada Inc. employs approximately 600 people to serve the evolving needs of patients and the healthcare system and invests over $30 million in R&D yearly in the country. For more information visit SOURCE Novartis Pharmaceuticals Canada Inc.
